MOF-Based Polymeric Nanocomposite Films as Potential Materials for Drug Delivery Devices in Ocular Therapeutics

Gándara-Loe, Jesús; Souza, Barbara; Missyul, Alexander; Giraldo, Germán Urrego; Tan, Jin‐Chong; Silvestre-Albero, Joaquín

doi:10.1021/acsami.0c07517

Cited by 79 publications

(42 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This functional MOFs-based ocular polymeric device exhibited excellent adsorption and release performance for brimonidine tartrate owing to large tetrahedral and octahedral cages of UiO-67 and realized a controllable and extended drug release in glaucoma therapy ( Fig. 10 B) 218 .…”

Section: Applications Of Mofs In Therapy and Drug Deliverymentioning

confidence: 99%

“…Another research utilizing Zr-based UiO-67 loaded brimonidine tartrate and polyurethane nanocomposite films as novel ocular therapeutics was developed by Gandara-Loe et al 218 . This functional MOFs-based ocular polymeric device exhibited excellent adsorption and release performance for brimonidine tartrate owing to large tetrahedral and octahedral cages of UiO-67 and realized a controllable and extended drug release in glaucoma therapy ( Fig.…”

Section: Applications Of Mofs In Therapy and Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Metal-organic frameworks for advanced drug delivery

et al. 2021

Acta Pharmaceutica Sinica B

275

116

View full text Add to dashboard Cite

Metal-organic frameworks (MOFs), comprised of organic ligands and metal ions/metal clusters via coordinative bonds are highly porous, crystalline materials. Their tunable porosity, chemical composition, size and shape, and easy surface functionalization make this large family more and more popular for drug delivery. There is a growing interest over the last decades in the design of engineered MOFs with controlled sizes for a variety of biomedical applications. This article presents an overall review and perspectives of MOFs-based drug delivery systems (DDSs), starting with the MOFs classification adapted for DDSs based on the types of constituting metals and ligands. Then, the synthesis and characterization of MOFs for DDSs are developed, followed by the drug loading strategies, applications, biopharmaceutics and quality control. Importantly, a variety of representative applications of MOFs are detailed from a point of view of applications in pharmaceutics, diseases therapy and advanced DDSs. In particular, the biopharmaceutics and quality control of MOFs-based DDSs are summarized with critical issues to be addressed. Finally, challenges in MOFs development for DDSs are discussed, such as biostability, biosafety, biopharmaceutics and nomenclature.

show abstract

Section: Applications Of Mofs In Therapy and Drug Deliverymentioning

confidence: 99%

Section: Applications Of Mofs In Therapy and Drug Deliverymentioning

confidence: 99%

Metal-organic frameworks for advanced drug delivery

et al. 2021

Acta Pharmaceutica Sinica B

275

116

View full text Add to dashboard Cite

show abstract

“…The MOF-based polymer nanocomposite showed a prolonged drug release (14 days). [216] Photoreceptor Degeneration…”

Section: Mg G −1mentioning

confidence: 99%

Biomedical Applications of Metal−Organic Frameworks for Disease Diagnosis and Drug Delivery: A Review

2022

View full text Add to dashboard Cite

Metal−organic frameworks (MOFs) are a novel class of porous hybrid organic−inorganic materials that have attracted increasing attention over the past decade. MOFs can be used in chemical engineering, materials science, and chemistry applications. Recently, these structures have been thoroughly studied as promising platforms for biomedical applications. Due to their unique physical and chemical properties, they are regarded as promising candidates for disease diagnosis and drug delivery. Their well-defined structure, high porosity, tunable frameworks, wide range of pore shapes, ultrahigh surface area, relatively low toxicity, and easy chemical functionalization have made them the focus of extensive research. This review highlights the up-to-date progress of MOFs as potential platforms for disease diagnosis and drug delivery for a wide range of diseases such as cancer, diabetes, neurological disorders, and ocular diseases. A brief description of the synthesis methods of MOFs is first presented. Various examples of MOF-based sensors and DDSs are introduced for the different diseases. Finally, the challenges and perspectives are discussed to provide context for the future development of MOFs as efficient platforms for disease diagnosis and drug delivery systems.

show abstract

“…However, the long‐term frequent use of a variety of eye drops or oculentum not only increases the undesirable side effects of the drug but also reduces the compliance of patients. [ 10–12 ] Therefore, the development of a new drug delivery system that can both improve drug bioavailability and patient compliance simultaneously in the treatment of glaucoma is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Lollipop‐Inspired Multilayered Drug Delivery Hydrogel for Dual Effective, Long‐Term, and NIR‐Defined Glaucoma Treatment

Wang

Song

Huang

et al. 2021

Macromolecular Bioscience

View full text Add to dashboard Cite

Glaucoma is an ophthalmic disease that is characterized by elevated intraocular pressure (IOP). Eye drops are the preferred choice to reduce IOP for the treatment of glaucoma. However, the bioavailability of eye drops is low (<5%). Their long‐term frequent administration cannot ensure patient compliance, which is the main reason for treatment failure. Inspired by lollipop, herein, a multilayered sodium alginate‐chitosan (SA‐CS) hydrogel ball (HB) decorated by zinc oxide‐modified biochar (ZnO‐BC) is developed as a new drug delivery system. The multilayer structure encapsulate timolol maleate (TM) and levofloxacin inside the different layers to realize the sustained release of drugs, which can control ocular hypertension and prevent infection effectively. The results show that the release of TM can be sustained in vitro for longer than 2 weeks. Moreover, IOP is also effectively reduced in vivo. Meanwhile, the photothermal conversion activity of ZnO‐BC can regulate drug release on demand after stimulation by near‐infrared irradiation. More importantly, the designed HB also shows good biocompatibility and antibacterial properties in vitro and in vivo. In summary, ZnO‐BC‐SA‐CS HB can effectively reduce IOP and is expected to replace the classical tedious eye drop strategy, having potential utilization value in the treatment of glaucoma.

show abstract

MOF-Based Polymeric Nanocomposite Films as Potential Materials for Drug Delivery Devices in Ocular Therapeutics

Cited by 79 publications

References 54 publications

Metal-organic frameworks for advanced drug delivery

Metal-organic frameworks for advanced drug delivery

Biomedical Applications of Metal−Organic Frameworks for Disease Diagnosis and Drug Delivery: A Review

Lollipop‐Inspired Multilayered Drug Delivery Hydrogel for Dual Effective, Long‐Term, and NIR‐Defined Glaucoma Treatment

Contact Info

Product

Resources

About